| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 6339919
[patent_doc_number] => 20100247521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-09-30
[patent_title] => 'Therapeutic and Diagnostic Methods Using TIM-3'
[patent_app_type] => utility
[patent_app_number] => 12/739639
[patent_app_country] => US
[patent_app_date] => 2008-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 23670
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0247/20100247521.pdf
[firstpage_image] =>[orig_patent_app_number] => 12739639
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/739639 | Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors | Oct 26, 2008 | Issued |
Array
(
[id] => 6506108
[patent_doc_number] => 20100216119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-26
[patent_title] => 'Diagnostic Methods for HIV Infection'
[patent_app_type] => utility
[patent_app_number] => 12/682992
[patent_app_country] => US
[patent_app_date] => 2008-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 22371
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0216/20100216119.pdf
[firstpage_image] =>[orig_patent_app_number] => 12682992
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/682992 | Diagnostic Methods for HIV Infection | Oct 14, 2008 | Abandoned |
Array
(
[id] => 6492539
[patent_doc_number] => 20100093618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-04-15
[patent_title] => 'POLYPEPTIDE CAPABLE OF INHIBITING HIV-1 TRANSCRIPTION AND REPLICATION AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/252279
[patent_app_country] => US
[patent_app_date] => 2008-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 14500
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0093/20100093618.pdf
[firstpage_image] =>[orig_patent_app_number] => 12252279
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/252279 | POLYPEPTIDE CAPABLE OF INHIBITING HIV-1 TRANSCRIPTION AND REPLICATION AND USES THEREOF | Oct 14, 2008 | Abandoned |
Array
(
[id] => 5392417
[patent_doc_number] => 20090209730
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-20
[patent_title] => 'METHOD FOR GENE TRANSFER INTO TARGET CELLS WITH RETROVIRUS'
[patent_app_type] => utility
[patent_app_number] => 12/241581
[patent_app_country] => US
[patent_app_date] => 2008-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 27773
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0209/20090209730.pdf
[firstpage_image] =>[orig_patent_app_number] => 12241581
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/241581 | Enhancement of retroviral gene transduction employing polypeptides comprising the fibronectin heparin II binding domain | Sep 29, 2008 | Issued |
Array
(
[id] => 9238701
[patent_doc_number] => 08603490
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-12-10
[patent_title] => 'Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate'
[patent_app_type] => utility
[patent_app_number] => 12/286159
[patent_app_country] => US
[patent_app_date] => 2008-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 26
[patent_no_of_words] => 11547
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12286159
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/286159 | Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate | Sep 28, 2008 | Issued |
Array
(
[id] => 4497458
[patent_doc_number] => 07947807
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-05-24
[patent_title] => 'Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3)'
[patent_app_type] => utility
[patent_app_number] => 12/284245
[patent_app_country] => US
[patent_app_date] => 2008-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11509
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/947/07947807.pdf
[firstpage_image] =>[orig_patent_app_number] => 12284245
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/284245 | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) | Sep 18, 2008 | Issued |
Array
(
[id] => 5270990
[patent_doc_number] => 20090074766
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-03-19
[patent_title] => 'Methods of inhibiting HIV-2 infection'
[patent_app_type] => utility
[patent_app_number] => 12/283482
[patent_app_country] => US
[patent_app_date] => 2008-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 36632
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 33
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0074/20090074766.pdf
[firstpage_image] =>[orig_patent_app_number] => 12283482
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/283482 | Methods of inhibiting HIV-2 infection | Sep 11, 2008 | Abandoned |
Array
(
[id] => 6340138
[patent_doc_number] => 20100247558
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-09-30
[patent_title] => 'PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE'
[patent_app_type] => utility
[patent_app_number] => 12/675334
[patent_app_country] => US
[patent_app_date] => 2008-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 17232
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0247/20100247558.pdf
[firstpage_image] =>[orig_patent_app_number] => 12675334
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/675334 | Peptides inducing a CD4i conformation in HIV gp120 while retaining vacant CD4 binding site | Aug 27, 2008 | Issued |
Array
(
[id] => 111102
[patent_doc_number] => 07718180
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-05-18
[patent_title] => 'Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site'
[patent_app_type] => utility
[patent_app_number] => 12/229863
[patent_app_country] => US
[patent_app_date] => 2008-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 20924
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/718/07718180.pdf
[firstpage_image] =>[orig_patent_app_number] => 12229863
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/229863 | Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site | Aug 26, 2008 | Issued |
Array
(
[id] => 5520909
[patent_doc_number] => 20090028890
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-01-29
[patent_title] => 'Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein'
[patent_app_type] => utility
[patent_app_number] => 12/229865
[patent_app_country] => US
[patent_app_date] => 2008-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 20921
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0028/20090028890.pdf
[firstpage_image] =>[orig_patent_app_number] => 12229865
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/229865 | Immunizing compositions comprising recombinant attenuated self-replicating viral RNA replicons encoding an epitope obtained from the HIV-1 matrix protein myrstate binding site | Aug 26, 2008 | Issued |
Array
(
[id] => 7997043
[patent_doc_number] => 08080369
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-12-20
[patent_title] => 'Methods for activating peripheral blood mononuclear cells (PBMCs) by administering human immunodeficiency virus (HIV) Tat under physiological oxygen levels'
[patent_app_type] => utility
[patent_app_number] => 12/196663
[patent_app_country] => US
[patent_app_date] => 2008-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15448
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/080/08080369.pdf
[firstpage_image] =>[orig_patent_app_number] => 12196663
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/196663 | Methods for activating peripheral blood mononuclear cells (PBMCs) by administering human immunodeficiency virus (HIV) Tat under physiological oxygen levels | Aug 21, 2008 | Issued |
Array
(
[id] => 5575010
[patent_doc_number] => 20090142371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-06-04
[patent_title] => 'HIV RECOMBINANT VACCINE'
[patent_app_type] => utility
[patent_app_number] => 12/195778
[patent_app_country] => US
[patent_app_date] => 2008-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 11785
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0142/20090142371.pdf
[firstpage_image] =>[orig_patent_app_number] => 12195778
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/195778 | HIV RECOMBINANT VACCINE | Aug 20, 2008 | Abandoned |
Array
(
[id] => 5473655
[patent_doc_number] => 20090246821
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-01
[patent_title] => 'PEROXIREDOXIN DRUGS FOR TREATMENT OF HIV-1 INFECTION AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/195103
[patent_app_country] => US
[patent_app_date] => 2008-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 15381
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0246/20090246821.pdf
[firstpage_image] =>[orig_patent_app_number] => 12195103
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/195103 | PEROXIREDOXIN DRUGS FOR TREATMENT OF HIV-1 INFECTION AND METHODS OF USE THEREOF | Aug 19, 2008 | Abandoned |
Array
(
[id] => 4521075
[patent_doc_number] => 07951377
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-05-31
[patent_title] => 'Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens'
[patent_app_type] => utility
[patent_app_number] => 12/192015
[patent_app_country] => US
[patent_app_date] => 2008-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 109
[patent_figures_cnt] => 46
[patent_no_of_words] => 13434
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/951/07951377.pdf
[firstpage_image] =>[orig_patent_app_number] => 12192015
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/192015 | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens | Aug 13, 2008 | Issued |
Array
(
[id] => 5526797
[patent_doc_number] => 20090196874
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-06
[patent_title] => 'ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS'
[patent_app_type] => utility
[patent_app_number] => 12/190802
[patent_app_country] => US
[patent_app_date] => 2008-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 24122
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0196/20090196874.pdf
[firstpage_image] =>[orig_patent_app_number] => 12190802
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/190802 | Methods for detecting enveloped virus infections by measuring cell surface TSG101 | Aug 12, 2008 | Issued |
Array
(
[id] => 5533479
[patent_doc_number] => 20090233267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-09-17
[patent_title] => 'Methylated Tat Polypeptides and Methods of Use Thereof'
[patent_app_type] => utility
[patent_app_number] => 12/190414
[patent_app_country] => US
[patent_app_date] => 2008-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 25078
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0233/20090233267.pdf
[firstpage_image] =>[orig_patent_app_number] => 12190414
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/190414 | Methylated tat polypeptides and methods of use thereof | Aug 11, 2008 | Issued |
Array
(
[id] => 6038442
[patent_doc_number] => 20110091491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-04-21
[patent_title] => 'HIV-1 GP41 NEUTRALIZATION DOMAIN AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/672585
[patent_app_country] => US
[patent_app_date] => 2008-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8437
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0091/20110091491.pdf
[firstpage_image] =>[orig_patent_app_number] => 12672585
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/672585 | HIV-1 GP41 neutralization domain and use thereof | Aug 10, 2008 | Issued |
Array
(
[id] => 5429071
[patent_doc_number] => 20090088381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-04-02
[patent_title] => 'COMPOSITIONS CONTAINING ANTI-HIV PEPTIDES AND METHODS FOR USE'
[patent_app_type] => utility
[patent_app_number] => 12/184409
[patent_app_country] => US
[patent_app_date] => 2008-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 15168
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0088/20090088381.pdf
[firstpage_image] =>[orig_patent_app_number] => 12184409
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/184409 | Microbicidal compositions comprising human CD38 polypeptides derived from the extracellular membrane-proximal region | Jul 31, 2008 | Issued |
Array
(
[id] => 5336756
[patent_doc_number] => 20090053220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-02-26
[patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV INFECTION OF T CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/182808
[patent_app_country] => US
[patent_app_date] => 2008-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 13363
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0053/20090053220.pdf
[firstpage_image] =>[orig_patent_app_number] => 12182808
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/182808 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF HIV INFECTION OF T CELLS | Jul 29, 2008 | Abandoned |
Array
(
[id] => 5296006
[patent_doc_number] => 20090010932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-01-08
[patent_title] => 'GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV'
[patent_app_type] => utility
[patent_app_number] => 12/179399
[patent_app_country] => US
[patent_app_date] => 2008-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 27388
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0010/20090010932.pdf
[firstpage_image] =>[orig_patent_app_number] => 12179399
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/179399 | Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies | Jul 23, 2008 | Issued |